burns. Burn of unspecified body region, unspecified degree
Conditions
Interventions
Intervention 1: Intervention group: 3 capsules of 100 mg of coenzyme Q10 supplement daily (3 times, one capsule of 100 mg each time, immediately after breakfast, lunch and dinner, a total of 300 mg of
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Age 65-18 years Accept informed consent by the patient or his mobile Gastrointestinal tract with normal function Has a burn above 20% Proper fluid recovery in the first 24 hours and hemodynamic stability after 48 hours
Exclusion criteria
Exclusion criteria: • Patients who are hospitalized for less than 48 hours or do not have stable conditions to start oral or tube feeding. • Dissatisfaction of the patient or family. • Patients with cancer undergoing chemotherapy and cisplatin. Patients receiving warfarin. • Pregnancy Severe and progressive septic shock or sepsis Hypovolemic shock in the first 48 hours Patients who are expected to die within one week of admission. • Patients with a history of certain diseases such as congenital and immune disorders, cirrhosis and pancreatitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C reactive Protein (CRP). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Erythrocyte sedimentation rate (ESR). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Total antioxidant capacity. Timepoint: At baseline and end f the study. Method of measurement: Commercial diagnostic kit.;Total oxidative stress. Timepoint: At baseline and end of the study. Method of measurement: Commercial diagnostic kit.;White blood cells (WBC). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Body temperature. Timepoint: At baseline and end of the study. Method of measurement: Measurement with a thermometer.;High-density lipoprotein (HDL). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Triglycerides. Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Fasting blood sugar (FBS). Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Blood urea nitrogen. Timepoint: At baseline and end of the study. Method of measurement: ELISA test.;Creatinine. Timepoint: At baseline and end of the study. Method of measurement: ELISA test. | — |
Secondary
| Measure | Time frame |
|---|---|
| 28-day mortality rate. Timepoint: End of the study. Method of measurement: Mathematically dividing the number of dead people by the total number of people using hospital records or telephone follow-up.;Duration of hospitalization. Timepoint: End of the study. Method of measurement: Hospital records. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Bagherniya
Esfahan University of Medical Sciences
Outcome results
None listed